Search by Drug Name or NDC
NDC 00078-0659-67 ENTRESTO 24; 26 mg/1; mg/1 Details
ENTRESTO 24; 26 mg/1; mg/1
ENTRESTO is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is SACUBITRIL; VALSARTAN.
MedlinePlus Drug Summary
The combination of valsartan and sacubitril is usually used in combination with other medications to lower the risk of death and hospitalization in adults with certain types of heart failure. The combination of valsartan and sacubitril is also used to treat certain types of heart failure in children 1 year of age and older. Valsartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. Sacubitril is in a class of medications called neprilysin inhibitors. It works to help control blood volume.
Related Packages: 00078-0659-67Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Valsartan and Sacubitril
Product Information
| NDC | 00078-0659 |
|---|---|
| Product ID | 0078-0659_d32b959b-b270-43bf-89de-639d833289d9 |
| Associated GPIs | 40992002600320 |
| GCN Sequence Number | 074408 |
| GCN Sequence Number Description | sacubitril/valsartan TABLET 24 MG-26MG ORAL |
| HIC3 | A4L |
| HIC3 Description | ANGIOTENSIN RECEPT-NEPRILYSIN INHIBITOR COMB(ARNI) |
| GCN | 39046 |
| HICL Sequence Number | 042256 |
| HICL Sequence Number Description | SACUBITRIL/VALSARTAN |
| Brand/Generic | Brand |
| Proprietary Name | ENTRESTO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Sacubitril and Valsartan |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 24; 26 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | SACUBITRIL; VALSARTAN |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA207620 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0659-67 (00078065967)
| NDC Package Code | 0078-0659-67 |
|---|---|
| Billing NDC | 00078065967 |
| Package | 180 TABLET, FILM COATED in 1 BOTTLE (0078-0659-67) |
| Marketing Start Date | 2015-07-07 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 10.9979 |
| Pricing Unit | EA |
| Effective Date | 2024-01-10 |
| NDC Description | ENTRESTO 24 MG-26 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |